Active, not recruitingPhase 2NCT04557449
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Studying Liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- PF-07220060(drug)
- Enrollment
- 362 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- Ellison Institute, Los Angeles, California, United States
- Smilow Cancer Hospital at Yale - New Haven, New Haven, Connecticut, United States
- Yale-New Haven Hospital-Yale Cancer Center, New Haven, Connecticut, United States
- Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, United States
- Brigham & Women's Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Dana Farber Cancer Institute- Chestnut Hill, Newton, Massachusetts, United States
- START Midwest, Grand Rapids, Michigan, United States
- Sarah Cannon Research Institute - Pharmacy, Nashville, Tennessee, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
- Fundación Cenit Para La Investigación En Neurociencias, CABA, Ciudad Autã³noma de Buenos Aires, Argentina
- Fundación Respirar, Buenos Aires, Argentina
- Clínica Universitaria Reina Fabiola, Córdoba, Argentina
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04557449 on ClinicalTrials.govOther trials for Liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07377747Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal LiposarcomaAustralia and New Zealand Sarcoma Association
- RECRUITINGNCT06436846Genomic Risk in Retroperitoneal SarcomaFox Chase Cancer Center
- RECRUITINGPHASE1, PHASE2NCT04785196APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid TumorsAscentage Pharma Group Inc.
- RECRUITINGNCT04699292International Prospective Registry on Local Treatment Approaches in MLSThe Netherlands Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT04438824Palbociclib and INCMGA00012 in People With Advanced LiposarcomaMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT03361436Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by SurgeryOHSU Knight Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT03307616Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before SurgeryM.D. Anderson Cancer Center